轻度至中度htn矩阵厄贝沙坦hctz.pdfVIP

AJH 1999;12:797– 805 Matrix Study of Irbesartan With Hydrochlorothiazide in Mild-to-Moderate Hypertension M. Kochar, R. Guthrie, J. Triscari, K. Kassler-Taub, and R.A. Reeves The purpose of this study was to assess the safety groups, and 28.1 to 215.0 for the combination and antihypertensive dose-response effects of groups. Irbesartan plus HCTZ produced additive irbesartan and hydrochlorothiazide (HCTZ) in reductions in both SeDBP and seated systolic BP, patients with mild-to-moderate hypertension. After with at least one combination producing greater BP a 4- to 5-week single-blind cebo lead-in period, reduction than either drug alone (P .001). All 683 patients with seated diastolic blood pressure treatments were well tolerated; there were no (SeDBP) between 95 and110 mm Hg were treatment-related serious adverse events. Irbesartan randomized to receive once-daily dosing with one tended to ameliorate the dose-related biochemical of 16 different double-blind, fixed combinations of abnormalities associated with HCTZ alone. In irbesartan (0, 37.5, 100, and 300 mg irbesartan) and conclusion, the combination of HCTZ in doses up HCTZ (0, 6.25, 12.5, and 25 mg HCTZ) for 8 weeks. to 25 mg with irbesartan, in doses up to 300 mg, is The primary efficacy variable was the change from safe and produces dose-dependent reductions in BP. baseline in trough SeDBP after 8 weeks of therapy. Am J Hypertens 1999;12:797– 805 © 1999 Data were yzed by response surface modeling. American Journal of Hypertension, . At Week 8, mean changes from baseline in trough SeDBP (mm Hg) ranged from 23.5 for cebo, : Irbesartan, hydrochlorothiazide, 27.1 to 2